AmpliTech Group Becomes First US Based Company To Achieve O-RAN Certification For Its ORAN 5G 64T64R MIMO Radio Platform Certification Confirms Standards-Based Readiness for High-Capacity 5G Networks in Dense Environments GlobeNewswire January 20, 2026 HAUPPAUGE, N.Y., Jan. 20, 2026 (GLOBE NEWSWIRE) — AmpliTech Group, Inc. (NASDAQ: AMPG), today announced that its flagship 5G Open RAN […]

Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch GlobeNewswire January 20, 2026 MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides an update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4 2025). Q4

Woodward Schedules Fiscal 2026 First Quarter Earnings Release and Conference Call GlobeNewswire January 20, 2026 FORT COLLINS, Colo., Jan. 20, 2026 (GLOBE NEWSWIRE) — Woodward, Inc. (NASDAQ: WWD) announced today that it expects to report its fiscal 2026 first quarter financial results at approximately 4:00 p.m. ET on Monday, February 2, 2026. A news release

BPGbio Receives FDA Orphan Drug Designation for BPM31510 for the Treatment of Primary CoQ10 Deficiency GlobeNewswire January 20, 2026 BOSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) — BPGbio, Inc., a leading biology-first, AI-powered clinical-stage biopharma company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead candidate,

BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI(R) Label Expansion in the At-Home Setting GlobeNewswire January 20, 2026 sNDA submission supports the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with IGALMI(R) Submission timeline supports potential approval of IGALMI(R) label expansion

Plug Power CEO Andy Marsh to Host Reddit AMA on January 22, 2026 Live Q&A Addressing Key Questions Ahead of Plug's January 29, 2026 Special Meeting GlobeNewswire January 20, 2026 SLINGERLANDS, N.Y., Jan. 20, 2026 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, announces

Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis GlobeNewswire January 20, 2026 Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following longer 8-week treatment 75% of soquelitinib patients achieved EASI 75, 25% achieved EASI 90 and

Beneficient Announces Early Payoff of Debt GlobeNewswire January 20, 2026 DALLAS, Jan. 20, 2026 (GLOBE NEWSWIRE) — Beneficient (Nasdaq: BENF), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today announced that it has completed the repayment of an aggregate of approximately $27.5

NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei Executive Chairman of the Board, Fu Wei, informed the Company of his intent to purchase up to $5,000,000 of the Company's American Depository Shares (ADSs) GlobeNewswire January 20, 2026 ROCKVILLE, Md., Jan. 20, 2026 (GLOBE NEWSWIRE) — NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company)

NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing GlobeNewswire January 20, 2026 VANCOUVER, British Columbia, Jan. 20, 2026 (GLOBE NEWSWIRE) — NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and